Imperial College London
Alternate

Jiri Pavlu

Faculty of Medicine, Department of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 8117j.pavlu Website

 
 
//

Location

 

Leuka Building R2.20Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pavlu:2012:10.1007/s12254-012-0042-z,
author = {Pavlu, J and Chakrabartty, J and Apperley, JF},
doi = {10.1007/s12254-012-0042-z},
journal = {Memo - Magazine of European Medical Oncology},
pages = {277--280},
title = {"Stem cell transplantation: Its importance today": Chronic myeloid leukaemia: Stem cell transplantation versus new drugs},
url = {http://dx.doi.org/10.1007/s12254-012-0042-z},
volume = {5},
year = {2012}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Allogeneic stem cell transplantation (SCT) had traditionally been the first-line therapy of chronic myeloid leukaemia (CML), but the introduction of tyrosine kinase inhibitors (TKI) has caused a major change to the treatment algorithm. The majority of patients in chronic phase obtain an excellent response to these oral agents with minimal toxicity. SCT is therefore used only in a minority of patients who do not achieve adequate response to first-, second- or even third-generation agents. Patients in accelerated phase are less likely to achieve an optimal response and for patients in blast phase, SCT continues to be the only therapy with curative potential although it is now increasingly used in combination with TKI. This review discusses the place of SCT in the current therapy of CML. © 2012 Springer-Verlag Wien.
AU  - Pavlu,J
AU  - Chakrabartty,J
AU  - Apperley,JF
DO  - 10.1007/s12254-012-0042-z
EP  - 280
PY  - 2012///
SN  - 1865-5041
SP  - 277
TI  - "Stem cell transplantation: Its importance today": Chronic myeloid leukaemia: Stem cell transplantation versus new drugs
T2  - Memo - Magazine of European Medical Oncology
UR  - http://dx.doi.org/10.1007/s12254-012-0042-z
VL  - 5
ER  -
Download